LDLRAD4 (low density lipoprotein receptor class A domain containing 4) functions as a negative regulator of TGF-β signaling by competing with ZFYVE9 and SMAD4 for interaction with phosphorylated SMAD2/3, thereby suppressing downstream transcriptional effects 1. This inhibitory role positions LDLRAD4 at the intersection of cell proliferation, differentiation, apoptosis, and epithelial-to-mesenchymal transition (EMT) regulation. Clinically, LDLRAD4 demonstrates paradoxical roles depending on tissue context. In hepatocellular carcinoma, elevated LDLRAD4 promotes tumorigenesis and metastasis through interaction with Nedd4, where it localizes to lysosomes 1. Conversely, in colorectal cancer, the antisense lncRNA LDLRAD4-AS1 suppresses LDLRAD4 expression to enhance EMT and metastasis, indicating LDLRAD4 acts as a tumor suppressor in this context 2. Beyond malignancy, LDLRAD4 associates with periodontitis-related phenotypes 3, abdominal aortic diameter 4, and rheumatoid arthritis progression, where hypomethylation correlates with inflammatory markers (ESR, CRP, DAS28) 5. LDLRAD4 expression also influences lipid metabolism-dependent tumor immunogenicity in KRAS-mutated lung cancer 6. These findings suggest LDLRAD4 functions as a context-dependent regulator with potential diagnostic and therapeutic relevance across multiple disease states.